Zoetis (NYSE:ZTS) Given a $140.00 Price Target at Argus

Zoetis (NYSE:ZTS) has been given a $140.00 target price by Argus in a research report issued on Wednesday, TipRanks reports. The brokerage presently has a “buy” rating on the stock. Argus’ target price would suggest a potential upside of 9.01% from the stock’s previous close.

Several other equities research analysts have also commented on ZTS. SunTrust Banks upped their price target on shares of Zoetis from $120.00 to $130.00 and gave the company a “hold” rating in a report on Tuesday, August 13th. BMO Capital Markets upped their price target on shares of Zoetis from $101.00 to $105.00 and gave the company a “market perform” rating in a report on Thursday, May 9th. Craig Hallum upped their price target on shares of Zoetis from $132.00 to $138.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Barclays increased their target price on shares of Zoetis from $120.00 to $135.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $130.00 target price (up from $116.00) on shares of Zoetis in a research note on Wednesday, June 12th. Seven investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $117.47.

NYSE:ZTS traded up $0.36 during mid-day trading on Wednesday, hitting $128.43. The company’s stock had a trading volume of 1,698,163 shares, compared to its average volume of 2,113,520. Zoetis has a 1 year low of $78.90 and a 1 year high of $129.48. The company has a debt-to-equity ratio of 2.74, a current ratio of 4.17 and a quick ratio of 2.87. The stock has a market cap of $61.43 billion, a price-to-earnings ratio of 41.03, a PEG ratio of 3.22 and a beta of 0.87. The business’s fifty day moving average is $121.62 and its two-hundred day moving average is $108.01.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $0.90 EPS for the quarter, beating the consensus estimate of $0.82 by $0.08. Zoetis had a net margin of 22.74% and a return on equity of 72.86%. The company had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.51 billion. During the same period in the prior year, the company earned $0.77 earnings per share. The firm’s revenue was up 9.3% on a year-over-year basis. Analysts anticipate that Zoetis will post 3.57 EPS for the current fiscal year.

In related news, EVP Roxanne Lagano sold 4,463 shares of the company’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $125.99, for a total transaction of $562,293.37. Following the completion of the transaction, the executive vice president now owns 33,190 shares in the company, valued at approximately $4,181,608.10. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Clinton A. Jr. Lewis sold 6,123 shares of the company’s stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $109.79, for a total transaction of $672,244.17. Following the transaction, the executive vice president now owns 49,369 shares of the company’s stock, valued at approximately $5,420,222.51. The disclosure for this sale can be found here. Over the last three months, insiders have sold 36,232 shares of company stock worth $4,310,371. Corporate insiders own 0.29% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in ZTS. BlackRock Inc. raised its holdings in Zoetis by 2.2% in the 1st quarter. BlackRock Inc. now owns 37,486,408 shares of the company’s stock valued at $3,773,759,000 after acquiring an additional 795,558 shares during the last quarter. Vanguard Group Inc. raised its holdings in Zoetis by 1.0% in the 2nd quarter. Vanguard Group Inc. now owns 36,765,577 shares of the company’s stock valued at $4,172,526,000 after acquiring an additional 346,167 shares during the last quarter. Polen Capital Management LLC raised its holdings in Zoetis by 0.9% in the 2nd quarter. Polen Capital Management LLC now owns 10,188,554 shares of the company’s stock valued at $1,156,299,000 after acquiring an additional 86,364 shares during the last quarter. FMR LLC raised its holdings in Zoetis by 12.2% in the 1st quarter. FMR LLC now owns 8,127,931 shares of the company’s stock valued at $818,239,000 after acquiring an additional 882,183 shares during the last quarter. Finally, Nuveen Asset Management LLC raised its holdings in Zoetis by 40,874.9% in the 2nd quarter. Nuveen Asset Management LLC now owns 7,078,826 shares of the company’s stock valued at $803,376,000 after acquiring an additional 7,061,550 shares during the last quarter. Hedge funds and other institutional investors own 90.42% of the company’s stock.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

See Also: Does the Dogs of the Dow strategy work?

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.